论文部分内容阅读
目的探讨荧光原位杂交(FISH)法检测乳腺癌HER-2基因扩增与免疫组化(IHC)法检测HER-2蛋白表达结果的相关性。方法采用FISH和IHC方法分别检测134例乳腺癌石蜡标本的HER-2基因扩增和HER-2蛋白表达。结果 45例HER-2蛋白表达为(-)的病例中,HER-2基因扩增均为阴性;33例HER-2蛋白表达为(+)的病例中,4例HER-2基因扩增阳性;44例HER-2蛋白表达为()的病例中,28例HER-2基因扩增阳性;12例HER-2蛋白表达为()的病例中,11例HER-2基因扩增阳性。FISH与IHC检测结果的总符合率为84.3%,两者呈显著相关(P<0.01)。结论 IHC可作为筛查乳腺癌患者HER-2的首选方法。当HER-2蛋白表达为(-)或()时,IHC和FISH检测的一致性较高;而对于IHC为(+)或()的患者应再进行FISH检测,以确定HER-2基因表达。
Objective To investigate the correlation between the amplification of HER-2 gene detected by fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) method in detecting HER-2 protein expression in breast cancer. Methods FISH and IHC methods were used to detect HER-2 gene amplification and HER-2 protein expression in 134 cases of breast cancer specimens. Results Among 45 cases with HER-2 protein expression, none of HER-2 gene amplification was negative. Of 33 cases with HER-2 protein expression (+), 4 cases of HER-2 gene amplification was positive ; Among 44 cases with HER-2 protein expression (), 28 cases were positive for HER-2 gene amplification and 11 cases were positive for HER-2 gene amplification in 12 cases. The total coincidence rate of FISH and IHC was 84.3%, which was significantly correlated with each other (P <0.01). Conclusion IHC can be used as a screening method for HER-2 in breast cancer patients. When the expression of HER-2 protein (-) or (), IHC and FISH detection of high consistency; and IHC (+) or () patients should be further FISH detection to determine HER-2 gene expression .